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1 Somatostatin (somatotropin release inhibiting factor; SRIF) acts via five G protein-coupled
receptors (sst1–sst5) that modulate multiple cellular effectors. The aim of this study was to compare
two functional effects of the human sst2 receptor stably expressed in CHO-K1 cells in a single
experiment using a duplex assay for intracellular calcium and serum response element (SRE)-driven
luciferase expression.
2 Intracellular calcium was measured using a fluorometric imaging plate reader II (FLIPR II).
SRIF-14 rapidly and transiently increased intracellular calcium with a pEC50 of 8.7470.03 (n¼ 52).
At 5 h after FLIPR II measurements, luciferase expression was determined. SRIF-14 concentration-
dependently increased luciferase expression (pEC50¼ 9.0670.03, n¼ 52).
3 Natural and synthetic agonist/antagonist ligands for SRIF receptors were tested in the duplex
assay. Correlation of agonist potencies and efficacies between the two responses were significant
(r2¼ 0.83 and 0.90, pEC50 and Emax, respectively).
4 Pertussis toxin pretreatment reduced SRIF-14/octreotide-mediated intracellular calcium increases
by 45–47% and luciferase expression by 95–98%.
5 Thapsigargin pretreatment abolished the SRIF-14/octreotide-mediated intracellular calcium
increase but had no effect on luciferase expression.
6 In conclusion, SRIF stimulates an increase in intracellular calcium and SRE-luciferase expression
via human sst2 receptors in CHO-K1 cells. The increase in luciferase is mediated via Gi/Go while
intracellular calcium increase is mediated by both Gi/Go proteins and pertussis toxin-insensitive G
proteins, and is mainly via release of calcium from intracellular stores. SRIF ligands display a similar
recognition profile suggesting that the ligand/receptor/G protein/effector interaction is similar for the
two parameters.
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Introduction
The neuropeptide somatostatin (somatotropin release inhibit-
ing factor; SRIF) acts via five G protein-coupled receptors
(sst1–sst5; Hoyer et al., 1995). According to structural and
pharmacological similarities, the five receptors can be classi-
fied in two groups – SRIF1 which consists of sst2, sst3 and sst5,
and SRIF2 which consists of sst1 and sst4 (Hoyer et al., 1995;
Hannon et al., 2002).
All five receptors are coupled to adenylyl cyclase via Gi/Go
proteins, leading to inhibition of cyclic AMP (cAMP)
accumulation (Patel et al., 1994; Carruthers et al., 1999;
Siehler & Hoyer, 1999b). In addition, the receptors have been
shown to modulate multiple cellular effectors including
phospholipase C, Ca2þ channels, Kþ channels, mitogen-
activated protein kinases (MAP kinases) and phosphotyrosine
phosphatases (Patel & Srikant, 1997; Meyerhof, 1998).
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